Skip to main content
. 2014 Oct 8;5(20):10180–10197. doi: 10.18632/oncotarget.2507

Figure 8. Antitumor activity of HS-133 against SkBr3 xenograft.

Figure 8

(A–B) Mice bearing subcutaneously implanted SkBr3 cells were intratumorally injected with HS-133 (5 mg/kg) twice a week for 19 days. (C-D) Mice bearing subcutaneously implanted SkBr3 cells were orally administered with HS-133 (10 mg/kg) daily for 21 days.